Royal Bank of Canada
RLMD icon

Royal Bank of Canada’s Relmada Therapeutics RLMD Stock Holding History

Royal Bank of Canada’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
95
-1,944
-95% -$9.2K ﹤0.01% 6940
2025
Q4 		$10K Buy
2,039
+2,038
+203,800% +$6.83K ﹤0.01% 6424
2025
Q3 		$0 Hold
1
– – ﹤0.01% 7467
2025
Q2 		$0 Buy
+1
New +$1 ﹤0.01% 7299
2024
Q4 		– Sell
-1,490
Closed -$5K – 7196
2024
Q3 		$5K Sell
1,490
-1,375
-48% -$4.45K ﹤0.01% 6512
2024
Q2 		$9K Buy
+2,865
New +$10.4K ﹤0.01% 6389
2024
Q1 		– Sell
-4,151
Closed -$17K – 7503
2023
Q4 		$17K Buy
4,151
+3,567
+611% +$10.6K ﹤0.01% 6365
2023
Q3 		$2K Sell
584
-508
-47% -$1.51K ﹤0.01% 6812
2023
Q2 		$3K Sell
1,092
-530
-33% -$1.47K ﹤0.01% 6800
2023
Q1 		$3K Sell
1,622
-8,669
-84% -$29.9K ﹤0.01% 6703
2022
Q4 		$36K Buy
10,291
+3,633
+55% +$31.9K ﹤0.01% 6065
2022
Q3 		$246K Buy
6,658
+174
+3% +$4.82K ﹤0.01% 4595
2022
Q2 		$123K Sell
6,484
-1,372
-17% -$29.9K ﹤0.01% 5193
2022
Q1 		$212K Sell
7,856
-1,681
-18% -$34.8K ﹤0.01% 5028
2021
Q4 		$215K Sell
9,537
-274
-3% -$6.09K ﹤0.01% 5270
2021
Q3 		$257K Buy
9,811
+284
+3% +$7.6K ﹤0.01% 4940
2021
Q2 		$305K Buy
9,527
+250
+3% +$8.68K ﹤0.01% 4707
2021
Q1 		$326K Buy
9,277
+8,878
+2,225% +$311K ﹤0.01% 4538
2020
Q4 		$13K Sell
399
-427
-52% -$14.7K ﹤0.01% 6273
2020
Q3 		$31K Buy
826
+800
+3,077% +$30.9K ﹤0.01% 5539
2020
Q2 		$1K Buy
+26
New +$1.1K ﹤0.01% 6474
2020
Q1 		– Sell
-36
Closed -$1K – 6969
2019
Q4 		$1K Buy
+36
New +$1.09K ﹤0.01% 6683

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Royal Bank of Canada's RLMD Position: Q1 2026 in Review

Royal Bank of Canada reduced its Relmada Therapeutics (RLMD) stake by 95% in Q1 2026, selling an estimated $9.2K and leaving 95 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6940.

Royal Bank of Canada first reported a position in RLMD in Q4 2019 and has held it in 22 quarters since. The position peaked at $326K in Q1 2021. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Royal Bank of Canada held 95 shares of Relmada Therapeutics worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 1,944 Relmada Therapeutics shares in Q1 2026, an estimated $9.2K.
  • Relmada Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6940 holding.
  • Royal Bank of Canada first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Royal Bank of Canada's Relmada Therapeutics position peaked at $326K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.